25 , 36 – 38 In our prospective study, mean BCVA improved steadily throughout the study but did not reach statistical significance up until the secondary endpoint (32 weeks).
← all excerpts
AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
1
—
—